Promega GmbH 1. Juli 2021

NanoLuc® Binary Technology-based Assays for SARS-CoV-2 Research and Drug/Vaccine Development

SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic. Understanding the biology and pathogenesis of 

SARS-CoV-2 is critical to accomplish the challenging task of developing effective anti-viral treatments and vaccines. 


In this webinar, we will introduce a selection of bioluminescent assays and molecular tools based on the versatile NanoLuc® Binary Technology (NanoBiT®). We will demonstrate how these assays allow for the investigation of various aspects of the SARS-CoV-2 life cycle and can be applied in the development of anti-viral drugs and vaccines.


You will learn:


•   About the principle and advantages of the NanoLuc® Binary Technology 


•   How NanoBiT® supports the analysis of virus-host interactions

•   How to study antiviral activities of therapeutic antibodies against 


Wednesday, July 7th, 2021 at 10:00 am CEST

Register here

Promega unterstützt bereits seit über 40 Jahren die Forschung und Entwicklung weltweit mit innovativen Produkten, technischer Beratung... [mehr]